Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has said that the US District Court for the District of Columbia has granted a request of the company's subsidiary, Teva Pharmaceuticals USA, that the FDA relist generic Risperdal US patent.
Subscribe to our email newsletter
Teva has also been granted 180-day exclusivity for a generic version of Janssen Pharmaceutical’s Risperdal (risperidone) tablets, which is used for the treatment of schizophrenia.
Teva expects final approval with exclusivity on June 29, 2008.